tenofovir disoproxil and emtricitabine

Phase 3Small molecule

RRutgers, The State University of New Jersey

tenofovir disoproxil and emtricitabine is one of 25 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

HIV InfectionsRecruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

HIV InfectionsPhase 3

Recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

tenofovir disoproxil and emtricitabine

RRutgers, The State University of New Jersey

Phase 3

1 2

Singulair

AstraZeneca

Preclinical

1 3

Benadryl

PParkedale

Preclinical

1 4

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 5

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

2 7

Netakimab

SSPH-BIOCAD (HK) Limited

Preclinical

1 8

Pfizer-Biontech COVID-19 Vaccine

PProvidence Therapeutics Holdings Inc.

Preclinical

4 9

T89

TTasly Pharmaceuticals, Inc.

Preclinical

2 10

Administration of Almitrine

CCentre Hospitalier Universitaire de Nice

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

HIV Infections

NCT06250504

Clinical

Trials by Indication[1]

COVID-191 trial

Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home

Completed·UUniversity Hospital, Caen·Phase 2/3·NCT04685512·60 enrolled

Prophylaxis1 trial

IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project

Unknown status·RRutgers, The State University of New Jersey·Phase 4·NCT03058835·125 enrolled

HIV Infections1 trial

Long-acting HIV Pre-Exposure Prophylaxis Integrated With Community-based Sexual and Reproductive Health in South Africa (LAPIS): A Hybrid (1a) Cluster Randomised Controlled Phase 3B Trial of Effectiveness and Implementation

Recruiting·AAfrica Health Research Institute·Phase 3·NCT06250504·2,052 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for tenofovir disoproxil and emtricitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tenofovir disoproxil and emtricitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tenofovir disoproxil and emtricitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rutgers, The State University of New Jersey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRutgers, The State University of New Jersey

tenofovir disoproxil and emtricitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

COVID-191 trial

Prophylaxis1 trial

HIV Infections1 trial

References

Drug Info

Quick Facts

Related News